U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07197034) titled 'The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial' on Sept. 21.
Brief Summary: The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS) when used in a long term setting. It will also teach us about the safety of ARD-101.
The main questions it aims to answer are:
What medical problems do participants have when taking ARD-101 in a long term setting
Does ARD-101 improve the total score of the HQCT-9 (hyperphagia questionnaire for clinical trials, 9 questions)?
Eligible participants will:
Have completed trea...